The CPNDS Clinical Practice Recommendations Group has issued a level B recommendation (moderate evidence base: at least one high-quality study or multiple moderate-quality studies) that pharmacogenomic testing for the variants RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 should be performed in all pediatric cancer patients with an indication for doxorubicin or daunorubicin therapy to stratify their cardiovascular risk. This evidence concerns the gene RARG and cancer.